SAGE News and Press, Sage Therapeutics Inc. From 11/10/23

2023-11-10 06:57:27 ET Summary Sage Therapeutics' flagship product, Zurzuvae for PPD, faces market adoption challenges due to its controlled substance status. Increasing R&D expenses and a high burn rate raise concerns about Sage's long-term financial sustainability. Sage'...

2023-11-08 07:40:46 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...

2023-11-07 18:02:21 ET It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter results. This was on a day when stocks were generally performing...

2023-11-07 15:27:08 ET SAGE Therapeutics, Inc. (SAGE) Q3 2023 Earnings Conference Call November 07, 2022, 08:00 ET Company Participants Ashley Kaplowitz - Director, IR Barry Greene - President, CEO & Director Christopher Benecchi - Chief Business Officer ...

2023-11-07 08:30:19 ET More on Sage Therapeutics Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024 Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage Therapeutics Q3 2023 Earnings Preview Sage granted FDA orphan...

2023-11-07 06:32:40 ET More on Sage Therapeutics Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024 Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage Therapeutics Q3 2023 Earnings Preview Sage granted FDA orphan...

ZURZUVAE™ (zuranolone), first and only oral treatment approved for adults with postpartum depression (PPD), designated Schedule IV by the DEA; progressing towards planned commercial availability in December Announces expected wholesale acquisition cost of ZURZUVAE of $15,900 ...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Sage Therapeutics Inc. (SAGE) is expected to report $-2.64 for Q3 2023

2023-11-06 15:12:41 ET More on Sage Therapeutics Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024 Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage granted FDA orphan tag for Huntington’s disease therapy ...